Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

This study has been completed.
Sponsor:
Collaborator:
Ministry of Health and Prevention
Information provided by:
Ringkobing Love Apotek
ClinicalTrials.gov Identifier:
NCT00916214
First received: June 1, 2009
Last updated: June 13, 2011
Last verified: September 2009
  Purpose

The aim of the project is to evaluate effectiveness of a multidimensional pharmaceutical care plan in improving compliance among elderly polypharmacy users at community pharmacy settings. The specific objective of the project is to determine effects of pharmaceutical care program on medication adherence and persistence among elderly polypharmacy users.


Condition Intervention Phase
Polypharmacy
Other: Pharmaceutical care program
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

Further study details as provided by Ringkobing Love Apotek:

Primary Outcome Measures:
  • change in medication adherence from run-in to the end of phase 1 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • persistence of mean medication adherence [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: June 2009
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention Other: Pharmaceutical care program
The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Both men and woman aged more than 65 years and taking more than 2 drugs

Exclusion Criteria:

  • Inhabitants of nursing homes
  • People receiving unit dose dispensing of medicine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00916214

Locations
Denmark
Ringkøbing Løve Apotek
Ringkøbing, Denmark, 6950
Sponsors and Collaborators
Ringkobing Love Apotek
Ministry of Health and Prevention
Investigators
Principal Investigator: Muhammad Saeed Ringkøbing apotek
  More Information

No publications provided

Responsible Party: Muhammad Saeed, Ringkøbing Løve Apotek
ClinicalTrials.gov Identifier: NCT00916214     History of Changes
Other Study ID Numbers: RLA Trial
Study First Received: June 1, 2009
Last Updated: June 13, 2011
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics
Denmark: The Ministry of Health & Prevention
Denmark: Datatilsynet

ClinicalTrials.gov processed this record on November 19, 2014